Mercedes
Salgado Fernández
Instituto de Salud Carlos III
Madrid, EspañaPublications in collaboration with researchers from Instituto de Salud Carlos III (1)
2018
-
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Oncologist, Vol. 23, Núm. 11, pp. 1271-e128